Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Company Overview

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Key Stats

• Today's Range: $40.00 to $40.00
• 50-Day Range: $40.00 to $40.00
• 52-Week Range: $15.25 to $43.00
• Volume: N/A
• Average Volume: 10,339 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.25
• Consensus Rating: Hold

CALT Stock Analysis - Frequently Asked Questions

How have CALT shares performed this year?

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 on January 1st, 2025. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001.
View the best growth stocks for 2025 here.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $52.36 million for the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 212.04% and a negative net margin of 30.18%.
Read the conference call transcript.

When did Calliditas Therapeutics AB (publ) IPO?

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 4/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALT
• CIK: 1795579
• Web: www.calliditas.se
• Phone: 46-0-841-130-05
• Fax: N/A
• Employees: 180
• Year Founded: 2004

Price Target and Rating

• Average Stock Price Target: $39.25
• High Stock Price Target: $40.00
• Low Stock Price Target: $39.00
• Potential Upside/Downside: -1.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,960,000.00
• Net Margins: -30.18%
• Pretax Margin: -29.40%
• Return on Equity: -212.04%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: 9.44
• Current Ratio: 2.69
• Quick Ratio: 2.59

Sales & Book Value

• Annual Sales: $1.60 billion
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 37.74

Miscellaneous

• Outstanding Shares: 29,790,000
• Free Float: 29,135,000
• Market Cap: $1.19 billion
• Optionable: Optionable
• Beta: 1.77